NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076

RecruitingPhase 1, Phase 2

Sponsor: Bristol-Myers Squibb

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Pumitamig, Ipilimumab

Countries: United States, Australia, Chile, China, France, Germany, Italy, Japan

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria

* Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Participants must have no prior systemic therapy for advanced/ unresectable HCC.
* Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria

* Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.
* Participants must not have an organ transplant or autoimmune disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Locations (67)
  • Duarte, California, United States
  • Los Angeles, California, United States
  • Chicago, Illinois, United States
  • Detroit, Michigan, United States
  • Hackensack, New Jersey, United States
  • Mineola, New York, United States
  • Portland, Oregon, United States
  • Portland, Oregon, United States
  • Nashville, Tennessee, United States
  • Nashville, Tennessee, United States
  • Seattle, Washington, United States
  • Camperdown, New South Wales, Australia
  • Westmead, New South Wales, Australia
  • Birtinya, Queensland, Australia
  • Parkville, Victoria, Australia
  • Santiago, Santiago Metropolitan, Chile
  • Santiago Region Metropolitana, Santiago Metropolitan, Chile
  • Hefei, Anhui, China
  • Beijing, Beijing Municipality, China
  • Chongqing, Chongqing Municipality, China
  • Fuzhou, Fujian, China
  • Guangzhou, Guangdong, China
  • Nanning, Guangxi, China
  • Harbin, Heilongjiang, China
  • Nanyang, Henan, China
  • Nanjing, Jiangsu, China
  • Nanchang, Jiangxi, China
  • Xi'an, Shaanxi, China
  • Xi'an, Shaanxi, China
  • Jinan, Shandong, China
  • + 37 more on CT.gov